|
1
|
Churg A, Muller NL and Wright JL:
Respiratory bronchiolitis/interstitial lung disease: Fibrosis,
pulmonary function, and evolving concepts. Arch Pathol Lab Med.
134:27–32. 2010.PubMed/NCBI
|
|
2
|
Yoshida M, Sakuma J, Hayashi S, Abe K,
Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y,
et al: A histologically distinctive interstitial pneumonia induced
by overexpression of the interleukin 6, transforming growth factor
beta 1, or platelet-derived growth factor B gene. Proc Natl Acad
Sci USA. 92:9570–9574. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gross TJ and Hunninghake GW: Idiopathic
pulmonary fibrosis. N Engl J Med. 345:517–525. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Todd NW, Luzina IG and Atamas SP:
Molecular and cellular mechanisms of pulmonary fibrosis.
Fibrogenesis tissue Repair. 5:112012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurundkar A and Thannickal VJ: Redox
mechanisms in age-related lung fibrosis. Redox Biol. 9:67–76. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lederer DJ and Martinez FJ: Idiopathic
pulmonary fibrosis. N Engl J Med. 378:1811–1823. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bagnato G and Harari S: Cellular
interactions in the pathogenesis of interstitial lung diseases. Eur
Respir Rev. 24:102–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official Ats/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J RespirCrit Care Med. 183:788–824. 2011. View Article : Google Scholar
|
|
9
|
GBD 2013 Mortality and Causes of Death
Collaborators: Global, regional, and national age-sex specific
all-cause and cause-specific mortality for 240 causes of death,
1990-2013: A systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 385:117–171. 2015. View Article : Google Scholar :
|
|
10
|
Lucero HA and Kagan HM: Lysyl oxidase: An
oxidative enzyme and effector of cell function. Cell Mol Life Sci.
63:2304–2316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kagan HM and Li W: Lysyl oxidase:
Properties, specificity, and biological roles inside and outside of
the cell. J Cell Biochem. 88:660–672. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Magdaleno F and Trebicka J: Selective
LOXL2 inhibition: Potent antifibrotic effects in ongoing fibrosis
and fibrosis regression. Gut. 66:1540–1541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Millanes-Romero A, Herranz N, Perrera V,
Iturbide A, Loubat- Casanovas J, Gil J, Jenuwein T, García de
Herreros A and Peiró S: Regulation of heterochromatin transcription
by Snail1/LOXL2 during epithelial-to-mesenchymal transition. Mol
Cell. 52:746–757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barry-Hamilton V, Spangler R, Marshall D,
McCauley S, Rodriguez HM, Oyasu M, Mikels A, vaysberg M, Ghermazien
H, Wai C, et al: Allosteric inhibition of lysyl oxidase-like-2
impedes the development of a pathologic microenvironment. Nat Med.
16:1009–1017. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aumiller V, Strobel B, Romeike M, Schuler
M, Stierstorfer BE and Kreuz S: Comparative analysis of lysyl
oxidase (like) family members in pulmonary fibrosis. Sci Rep.
7:1492017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hinz B, Phan SH, Thannickal VJ, Galli A,
Bochaton-Piallat ML and Gabbiani G: The myofibroblast: One
function, multiple origins. Am J Pathol. 170:1807–1816. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-β family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee CM, Park JW, Cho WK, Zhou Y, Han B,
Yoon PO, Chae J, Elias JA and Lee CG: Modifiers of TGF-β1 effector
function as novel therapeutic targets of pulmonary fibrosis. Korean
J Intern Med. 29:281–290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Medici D, Potenta S and Kalluri R:
Transforming growth factor-β2 promotes Snail-mediated
endothelial-mesenchymal transition through convergence of
Smad-dependent and Smad-independent signalling. Biochem J.
437:515–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng T, Liu Q, Zhang R, Zhang Y, Chen J,
Yu R and Ge G: Lysyl oxidase promotes bleomycin-induced lung
fibrosis through modulating inflammation. J Mol Cell Biol.
6:506–515. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei Y, Kim TJ, Peng DH, Duan D, Gibbons
DL, Yamauchi M, Jackson JR, Le Saux CJ, Calhoun C, Peters J, et al:
Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung
and tumor fibrosis. J Clin Invest. 127:3675–3688. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Mäki JM, Sormunen R, Lippo S,
Kaarteenaho-Wiik R, Soininen R and Myllyharju J: Lysyl oxidase is
essential for normal development and function of the respiratory
system and for the integrity of elastic and collagen fibers in
various tissues. Am J Pathol. 167:927–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chien JW, Richards TJ, Gibson KF, Zhang Y,
Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N
and O'Riordan T: serum lysyl oxidase-like 2 levels and idiopathic
pulmonary fibrosis disease progression. Eur Respir J. 43:1430–1438.
2014. View Article : Google Scholar
|
|
25
|
Moon HJ, Finney J, Ronnebaum T and Mure M:
Human lysyl oxidase-like 2. Bioorg Chem. 57:231–241. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barker HE, Bird D, Lang G and Erler JT:
Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Mol Cancer Res. 11:1425–1436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi SE, Jeon N, Choi HY, Shin JI, Jeong
HJ and Lim BJ: Lysyl oxidase-like 2 is expressed in kidney tissue
and is associated with the progression of tubulointerstitial
fibrosis. Mol Med Rep. 16:2477–2482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Senavirathna LK, Huang C, Yang X, Munteanu
MC, Sathiaseelan R, Xu D, Henke CA and Liu L: Hypoxia induces
pulmonary fibroblast proliferation through NFAt signaling. Sci Rep.
8:27092018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hansen NU, Karsdal MA, Brockbank S, Cruwys
S, Rønnow S and Leeming DJ: Tissue turnover of collagen type I, III
and elastin is elevated in the PCLS model of IPF and can be
restored back to vehicle levels using a phosphodiesterase
inhibitor. Respir Res. 17:762016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Reilly S, Ciechomska M, Cant R and van
Laar JM: Interleukin-6 (IL-6) trans signaling drives a
STAT3-dependent pathway that leads to hyperactive transforming
growth factor-β (TGF-β) signaling promoting sMAD3 activation and
fibrosis via Gremlin protein. J BiolChem. 289:9952–9960. 2014.
|
|
31
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and
Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in
snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
